CN Mobile Logo

Search form


Textbook of Lung Cancer

Textbook of Lung Cancer

Lung cancer is a global problem fueled by the continuous use of tobacco in most countries, despite efforts at expanding smoking cessation programs. Several advances in the diagnosis and treatment of lung cancer were achieved in the past decade. This progress notwithstanding, most lung cancer patients succumb to their illness, and few enjoy long-term survival.

The authors have attempted to list the recent advances in this concise, easy-to-read textbook, which is the official text of the International Association for the Study of Lung Cancer (IASLC).

This textbook consists of 17 chapters covering various topics on thoracic malignancies in a systematic fashion. The first 10 chapters provide an overview of lung cancer, with respect to etiology, epidemiology, pathology, diagnosis, and staging of the disease. This is followed by three chapters dedicated to the treatment of small-cell and non-small-cell lung cancer and mesothelioma. The final four chapters discuss issues related to palliation, complications, quality of life, and cost-effectiveness. Two unique appendices are also included: The first covers surgical techniques used in the management of lung cancer, expanding on the subject of perioperative care and complications, and the second provides a quick helpful reference to the most commonly used chemotherapeutic agents in this disease.

Throughout, distinguished authors from the United States, Europe, and Japan provide their analysis of the world literature regarding lung cancer, crossing continental barriers and achieving a true unification of visions. Despite the authors’ best efforts, however, some of the newest advances in this field did not receive adequate discussion. Among the topics that are insufficiently addressed are second-line therapy for non-small-cell lung cancer and promising results in this disease with the use of targeted therapy, such as epidermal growth factor receptor (EGFR) inhibitors and anti-vascular endothelial growth factor (VEGF) antibody.

Overall, the textbook has successfully compiled worldwide experiences in the field of lung cancer. The book in fact manages to outline the global vision on the subject rather than providing a skewed view of one country or region. It represents a concise reference for anyone interested in expanding his or her knowledge of this subject. It is hoped that the IASLC will continue to assemble such textbooks, which reflect the international vision of this organization and its members.

By clicking Accept, you agree to become a member of the UBM Medica Community.